Skip to content
Education
Isle of NAM
Epigenomics

Epigenomics

Table of Contents

Definition

Epigenomics is the systematic, genome-scale study of the epigenome: the complete set of chemical and structural modifications that regulates genome function without altering the underlying DNA sequence. Its conceptual foundation is the modern chromatin-centered definition of epigenetics, formulated as the structural adaptation of chromosomal regions so as to register, signal, or perpetuate altered activity states1. The field models the regulatory state of a cell, namely which genomic loci are transcriptionally active, poised, or silenced, and how that state is established, maintained, and reprogrammed during development and in response to physiological or environmental signals2.

The biological basis of epigenomics rests on several interlocking molecular mechanics. DNA methylation, predominantly the addition of a methyl group to the fifth carbon of cytosine within cytosine-guanine dinucleotides (CpG), is a durable marks that recruits methyl-binding proteins and modulates transcription factor access1 2. Post-translational histone modifications, including acetylation, methylation, phosphorylation, and ubiquitination, alter the electrostatic properties and compaction state of the nucleosome, thereby controlling chromatin fiber accessibility2. Nucleosome positioning and chromatin accessibility jointly determine the physical availability of promoters, enhancers, and other regulatory elements to the transcriptional machinery2. These mechanisms are executed by enzymatic classes conceptually organized as writers, such as DNA methyltransferases and histone acetyltransferases; erasers, such as histone deacetylases and demethylases; and readers, such as methyl-CpG-binding and bromodomain proteins, which interpret the marks to recruit downstream regulatory complexes2.

Purpose

The primary value proposition of epigenomics is that the genome sequence alone is an incomplete descriptor of cellular function. The genome sequence is essentially identical across the diverse cell types of an organism, whereas the epigenome is cell-type specific, dynamically regulated, and responsive to developmental and environmental cues; epigenomic profiling therefore supplies the regulatory layer of genome function that sequence data cannot provide2 3.

Epigenomics replaces and improves upon legacy regulatory models in two principal ways. First, it supersedes candidate-locus approaches, such as single-gene methylation-specific PCR and locus-specific chromatin assays, which test a priori hypotheses at a small number of predefined loci. Genome-wide, single-base-resolution methylome profiling demonstrated that widespread epigenomic differences exist between cell types, differences that candidate approaches are structurally incapable of discovering4. Second, it converts gene regulation from a piecemeal, hypothesis-driven inquiry into a systematic, data-driven mapping discipline supported by standardized reference resources5 6 7.

The human relevance of the field is substantial. Epigenetic disruption is mechanistically implicated in human disease, including cancer, imprinting disorders, and repeat-expansion syndromes, making the epigenome a direct target for disease modelling and therapy8. Epigenomic variation captures gene-environment interaction, which is central to the etiology of common complex disease3. Furthermore, individuals prenatally exposed to famine exhibited persistent methylation differences at the IGF2 differentially methylated region nearly six decades later, demonstrating that epigenomic marks constitute a durable biological record of the human environment9.

Methodology

The construction of an epigenomic dataset begins with the substrate: genomic DNA or native chromatin obtained from a defined, and ideally purified, cell population, because epigenomes are strictly cell-type specific. Reference consortia prioritize primary ex vivo tissues and stem-cell-derived lineages, including human embryonic stem cell derivatives generated through directed differentiation protocols with defined culture media, as the biological substrate of reference epigenome production6.

For DNA methylation profiling, the foundational technique is bisulfite genomic sequencing, a chemical conversion protocol in which unmethylated cytosines are deaminated to uracil while 5-methylcytosine remains unchanged, thereby providing a positive, single-nucleotide display of methylation status in individual DNA strands10. Coupling bisulfite conversion with high-throughput sequencing (whole-genome bisulfite sequencing, WGBS) produced the first genome-wide, single-base-resolution maps of methylated cytosines in a mammalian genome and revealed previously unknown methylation features, including non-CpG methylation in embryonic stem cells4. Bisulfite-treated reads demand specialized computational treatment because of the reduced sequence complexity; Bismark is a flexible aligner and methylation caller purpose-built for bisulfite sequencing applications11.

For histone modification and protein-DNA interaction profiling, chromatin immunoprecipitation coupled with massively parallel sequencing (ChIP-seq) identifies mammalian DNA sequences bound by transcription factors and associated with specific histone marks on a genome-wide scale12. Application of this approach to CD4+ T cells generated high-resolution genome-wide maps of twenty histone methylations, establishing the systematic profiling of the histone code as a core epigenomic methodology13.

For chromatin accessibility, the assay for transposase-accessible chromatin using sequencing (ATAC-seq) exploits direct in vitro transposition of native chromatin, simultaneously querying open chromatin regions, DNA-binding protein occupancy, and nucleosome positioning from small quantities of input material14.

Methodological standardization is achieved through large-scale consortia. The NIH Roadmap Epigenomics Mapping Consortium established reference protocols and a public resource of epigenomic maps for stem cells and primary ex vivo tissues, with rapid release of raw sequence data6. The ENCODE Project produced an integrated encyclopedia of DNA elements built on uniform assays across many cell types5. The International Human Epigenome Consortium coordinates the generation of a catalog of high-resolution reference epigenomes of major primary human cell types under common data and quality standards7.

Performance

Empirically, epigenomic methodology has proven robust at reference scale. Integrative analysis of 111 reference human epigenomes consolidated thousands of datasets across primary tissues and cell types into a unified compendium of chromatin-state maps and candidate regulatory elements15. The ENCODE encyclopedia assigned biochemical activity to the substantial majority of the human genome in at least one cell type and catalogued millions of candidate regulatory elements5.

As a quantitative benchmark of epigenomic information content, the multi-tissue epigenetic aging clock was developed from approximately 8,000 samples spanning 82 Illumina DNA methylation array datasets and 51 healthy tissues and cell types; the estimator, based on 353 CpG sites, reports near-zero age for embryonic and induced pluripotent stem cells and correlates with cell passage number, demonstrating that methylation data encode reproducible biological signals across tissues16. Reproducibility is further supported by consortium architecture: IHEC coordinates production of high-resolution reference epigenomes under shared standards7, and the Roadmap consortium’s policy of rapid raw-data release prior to publication was designed explicitly to enable community validation6.

Current technical boundaries remain material. Epigenome-wide association studies are susceptible to confounding by shifting cell-type composition within the profiled tissue, to reverse causation in which disease alters marks rather than the reverse, and to tissue specificity that limits extrapolation from accessible surrogate tissues; rigorous design and interpretation are therefore mandatory17. Bulk assays average signals across heterogeneous cell populations and can mask biologically meaningful states, which motivated the development of multiplex single-cell accessibility profiling by combinatorial cellular indexing and of parallel single-cell methylome and transcriptome sequencing, each of which trades resolution for sparser per-cell genome coverage18 19. Finally, deep whole-genome bisulfite sequencing remains resource intensive, constraining throughput in large cohort designs17.

Applications

Primary research applications include gene-regulatory biology and developmental biology, in which reference epigenomes define enhancer landscapes and chromatin states across lineages15; epigenome-wide association studies, which couple methylation profiling to epidemiological cohorts for common human disease17; cancer research, in which epigenetic silencing and global methylation disruption are core mechanisms8; and aging research, in which methylation clocks provide quantitative biomarkers of biological age16.

Industrial and clinical applications are established in several sectors. The therapeutic tractability of the epigenome is clinically validated: azacitidine and decitabine, nucleoside inhibitors of DNA methylation, are the standard of care for the treatment of myelodysplastic syndrome20. Epigenomic biomarker development is an active industrial area in oncology and environmental health, building on demonstrated persistence of exposure-associated methylation signatures9 and on the framework of epigenetic epidemiology linking genetic and environmental risk3.

Standardized contexts of use are anchored in the public reference infrastructure. ENCODE, the NIH Roadmap Epigenomics Mapping Consortium, and IHEC provide curated reference epigenomes, standardized assays, and quality metrics that serve as community benchmarks for both academic and industrial users5 6 7. Deployment stage is mature for research infrastructure, clinically advanced in hematology-oncology pharmacotherapy20, and progressing toward clinical readiness for methylation-based diagnostics, which remain primarily deployed in research and early translational settings at present17 16.

Variations

  • DNA Methylomics: The genome-wide, base-resolution profiling of cytosine methylation using bisulfite-based sequencing and methylation arrays, encompassing CpG and non-CpG methylation states across cell types10 4.
  • Chromatin Accessibility Profiling: The mapping of open chromatin regions, transcription factor occupancy, and nucleosome positioning, principally through ATAC-seq, which achieves genome-wide accessibility maps from limited input material14.
  • Histone Modification Profiling: The systematic charting of post-translational histone marks through ChIP-seq and related immunoprecipitation strategies, generating genome-wide maps of individual modifications and their combinatorial states12 13.
  • Single-Cell Epigenomics: The profiling of epigenetic states at cellular resolution using combinatorial indexing for accessibility and parallel methylome-transcriptome sequencing, resolving heterogeneity that bulk assays average away18 19.
  • Epigenome-Wide Association Studies: The epidemiological study design that associates methylation variation across the genome with disease phenotypes in human cohorts, extending genome-wide association methodology to the regulatory layer17.
  • Environmental Epigenomics: The study of environmental exposures, including prenatal nutrition and other exogenous factors, and their persistent effects on the human epigenome, bridging environmental health and regulatory biology3 9.

  1. Adrian Bird, Perceptions of epigenetics, Nature, 2007-05-24.
    A landmark perspective that codifies the modern chromatin-centered definition of epigenetics and surveys the principal molecular mechanisms, emphasizing DNA methylation, chromatin architecture, and the absence of any single epigene analogous to the gene. The paper frames epigenetics as the structural adaptation of chromosomal regions to register, signal, or perpetuate altered activity states, a definition adopted throughout the field. ↩︎ ↩︎

  2. C. David Allis and Thomas Jenuwein, The molecular hallmarks of epigenetic control, Nature Reviews Genetics, 2016-09.
    An authoritative review that organizes epigenetic mechanisms into the writer, eraser, and reader framework and describes how DNA methylation, histone modifications, nucleosome positioning, and non-coding RNA pathways jointly regulate genome function. The review consolidates two decades of mechanistic dissection into a set of molecular hallmarks that define the scope of modern epigenomics. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎

  3. Andrew P. Feinberg and M. Daniele Fallin, Epigenetics at the crossroads of genes and the environment, JAMA, 2015-09-15.
    A concise review positioning the epigenome as the molecular interface between genetic predisposition and environmental exposure in human disease. The article argues that epigenetic variation provides a mechanistic account of gene-environment interaction relevant to common complex disease, with direct implications for prevention and risk prediction in clinical medicine. ↩︎ ↩︎ ↩︎ ↩︎

  4. Ryan Lister, Mattia Pelizzola, Robert H. Dowen, R. David Hawkins, Gary Hon, Nono Tonti-Filippini, Joseph R. Nery, Leonard Lee, Zhen Ye, Que-Minh Ngo, Lee Edsall, Jessica Antosiewicz-Bourget, Ron Stewart, Ruoping Thompson, and Joseph R. Ecker, Human DNA methylomes at base resolution show widespread epigenomic differences, Nature, 2009-10-14.
    The first genome-wide, single-base-resolution methylome maps of human cells, generated by whole-genome bisulfite sequencing of embryonic stem cells and differentiated fibroblasts. The study revealed pervasive methylation differences between cell types and identified non-CpG methylation as a distinctive feature of embryonic stem cells. ↩︎ ↩︎ ↩︎

  5. ENCODE Project Consortium, An integrated encyclopedia of DNA elements in the human genome, Nature, 2012-09-05.
    The integrated analysis of the ENCODE project, synthesizing thousands of uniformly generated datasets across many human cell types into a genome-wide encyclopedia of candidate regulatory elements. The analysis assigned biochemical activity to the substantial majority of the human genome in at least one cell type and established a standardized reference resource for gene-regulatory studies. ↩︎ ↩︎ ↩︎ ↩︎

  6. Bradley E. Bernstein, John A. Stamatoyannopoulos, Joseph F. Costello, Bing Ren, Aleksandar Milosavljevic, Alexander Meissner, Manolis Kellis, Mikko K. Martens, Michael D. Beer, Jianping Fu, et al., The NIH Roadmap Epigenomics Mapping Consortium, Nature Biotechnology, 2010-10.
    The programmatic description of the NIH Roadmap Epigenomics Mapping Consortium, which produced a public resource of reference epigenomic maps for human stem cells and primary ex vivo tissues. The consortium prioritized rapid release of raw data and standardized assays across participating production centers, defining the operating model for community epigenome resources. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎

  7. Hendrik G. Stunnenberg, International Human Epigenome Consortium, and Martin Hirst, The International Human Epigenome Consortium: A Blueprint for Scientific Collaboration and Discovery, Cell, 2016-12.
    The blueprint of the International Human Epigenome Consortium, which coordinates the worldwide generation of a catalog of high-resolution reference epigenomes of major primary human cell types. The article describes the consortium’s governance, data standards, and quality metrics that harmonize epigenome production across international member projects. ↩︎ ↩︎ ↩︎ ↩︎

  8. Anna Portela and Manel Esteller, Epigenetic modifications and human disease, Nature Biotechnology, 2010-10-13.
    A comprehensive review of the role of epigenetic disruption in human disease, covering DNA methylation, histone modifications, chromatin remodeling, and non-coding RNAs in cancer, imprinting disorders, and other pathologies. The review positions the epigenome as both a disease mechanism and a therapeutic target in the clinical setting. ↩︎ ↩︎

  9. Bastiaan T. Heijmans, Elmar W. Tobi, Aryeh D. Stein, Hein Putter, Gerard J. Blauw, Elana S. Susser, P. Eline Slagboom, and L. H. Lumey, Persistent epigenetic differences associated with prenatal exposure to famine in humans, Proceedings of the National Academy of Sciences, 2008-10-28.
    A landmark study of individuals exposed prenatally to famine during the Dutch Hunger Winter of 1944-1945, which found persistent hypomethylation at the IGF2 differentially methylated region nearly six decades after exposure. The study provides direct human evidence that environmental conditions in early development leave durable marks on the epigenome. ↩︎ ↩︎ ↩︎

  10. Marianne Frommer, Louise E. McDonald, Douglas S. Millar, Christina M. Collis, Fiona Watt, Grigory W. Grigg, David M. Molloy, and Christine L. Paul, A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands, Proceedings of the National Academy of Sciences, 1992-03-01.
    The original description of bisulfite genomic sequencing, the chemical conversion upon which nearly all modern DNA methylation profiling is based. The protocol deaminates unmethylated cytosines to uracil while preserving 5-methylcytosine, enabling methylation status to be read as a sequence difference at single-nucleotide resolution. ↩︎ ↩︎

  11. Felix Krueger and Simon R. Andrews, Bismark: a flexible aligner and methylation caller for Bisulfite-Seq applications, Bioinformatics, 2011-07-01.
    The description of Bismark, the widely adopted alignment and methylation-calling tool purpose-built for bisulfite sequencing data. The tool handles the reduced sequence complexity and strand asymmetry introduced by bisulfite conversion, and it remains a standard component of the DNA methylomics analysis pipeline. ↩︎

  12. Gordon Robertson, Martin Hirst, Matthew Bainbridge, Misha Bilenky, Yongjun Zhao, Thomas Zeng, Ghia Euskirchen, Bridget Bernstein, Aldo Varhol, Nipun Bhardwaj, Steven Jones, et al., Genome-wide profiles of STAT1 DNA association using chromatin immunoprecipitation and massively parallel sequencing, Nature Methods, 2007-06.
    The foundational demonstration of ChIP-seq, combining chromatin immunoprecipitation with massively parallel sequencing to map transcription factor binding across a mammalian genome. The method established the template for all subsequent sequence-based profiling of protein-DNA interactions and histone modifications. ↩︎ ↩︎

  13. Artem Barski, Suresh Cuddapah, Keji Cui, Tae Young Roh, Dustin E. Schones, Zhibin Wang, Gang Wei, Ilya Chepelev, and Keji Zhao, High-resolution profiling of histone methylations in the human genome, Cell, 2007-05-18.
    The first systematic genome-wide mapping of histone methylation in human cells, producing high-resolution maps of twenty histone methylations in CD4+ T cells. The study linked specific histone marks to promoters, enhancers, and transcribed regions, providing the empirical basis for the systematic profiling of the histone code. ↩︎ ↩︎

  14. Jason D. Buenrostro, Beijing Gao, Michael A. Preissl, Luke K. Bauer, and William J. Greenleaf, Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position, Nature Methods, 2013-10.
    The original description of ATAC-seq, in which a hyperactive transposase inserts sequencing adapters directly into accessible regions of native chromatin. The method queries open chromatin, DNA-binding protein occupancy, and nucleosome positioning simultaneously from minute quantities of input material, and it has become the dominant chromatin accessibility assay. ↩︎ ↩︎

  15. Anshul Kundaje, Ali Mortazavi, Peter V. Khavari, Barbara Wold, Michael Snyder, R. David Hawkins, Jason Ernst, Richard Sandstrom, Hongcang Zhu, Anthony D. Zhang, et al., Integrative analysis of 111 reference human epigenomes, Nature, 2015-02-19.
    The flagship integrative analysis of the Roadmap Epigenomics Consortium, consolidating 111 reference human epigenomes across primary tissues and cell types. The study defined genomewide maps of chromatin states, regulatory elements, and expression quantitative trait loci, establishing the reference compendium against which subsequent epigenomic studies are interpreted. ↩︎ ↩︎

  16. Steve Horvath, DNA methylation age of human tissues and cell types, Genome Biology, 2013-10-10.
    The original description of the multi-tissue epigenetic aging clock, developed from approximately 8,000 samples across 82 Illumina DNA methylation array datasets encompassing 51 healthy tissues and cell types. The estimator, based on 353 CpG sites, predicts chronological age across tissues, shows near-zero age for pluripotent stem cells, correlates with cell passage number, and reveals substantial age acceleration in cancer tissues. ↩︎ ↩︎ ↩︎

  17. Vardhman K. Rakyan, Thomas A. Down, David J. Balding, and Stephan Beck, Epigenome-wide association studies for common human diseases, Nature Reviews Genetics, 2011-07.
    The foundational methodological review of epigenome-wide association study design, which extends genome-wide association methodology to DNA methylation variation in human cohorts. The article analyzes the design challenges that distinguish epigenetic from genetic epidemiology, including cell-type composition confounding, reverse causation, and tissue specificity. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎

  18. Darren A. Cusanovich, Andrew J. Hill, Delasa Aghamirzaie, R. Daza, Melissa M. Eliche, Andrew C. Gasper, et al., Multiplex single-cell profiling of chromatin accessibility by combinatorial cellular indexing, Science, 2015-08-07.
    The description of combinatorial cellular indexing applied to single-cell chromatin accessibility profiling (sciATAC-seq), demonstrating that thousands of individual cells can be profiled for accessibility states in a single experiment. The method established a scalable route to resolving cell-to-cell epigenetic heterogeneity within complex tissues. ↩︎ ↩︎

  19. Christoph Angermueller, M. D. Marks, F. Clarke, V. K. Lee, Sophia B. Clark, Gerry F. Krueger, Anja M. Preissl, et al., Parallel single-cell sequencing links transcriptional and epigenetic heterogeneity, Nature Methods, 2016-01-18.
    The description of scM&T-seq, a method for parallel genome-wide methylome and transcriptome sequencing within the same single cell. The approach enables direct association of epigenetic and transcriptional heterogeneity at cellular resolution, exemplifying the single-cell extension of the epigenomic toolkit. ↩︎ ↩︎

  20. Jean-Pierre J. Issa and Hagop M. Kantarjian, Targeting DNA methylation, Clinical Cancer Research, 2009-06-15.
    A clinical review of DNA methylation as a therapeutic target, describing the mechanism and clinical deployment of the nucleoside analogs azacitidine and decitabine, which trap DNA methyltransferases and produce hypomethylation. The article documents the status of these DNMT inhibitors as the standard of care for myelodysplastic syndrome, establishing the clinical validity of epigenetic therapy. ↩︎ ↩︎